NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $115.65 +3.15 (+2.80%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Lantheus Stock (NASDAQ:LNTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lantheus alerts:Sign Up Key Stats Today's Range$112.40▼$116.1650-Day Range$94.91▼$112.5052-Week Range$50.20▼$126.89Volume643,095 shsAverage Volume975,247 shsMarket Capitalization$8.02 billionP/E Ratio18.96Dividend YieldN/APrice Target$126.00Consensus RatingModerate Buy Company OverviewLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Lantheus Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks79th Percentile Overall ScoreLNTH MarketRank™: Lantheus scored higher than 79% of companies evaluated by MarketBeat, and ranked 246th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLantheus has only been the subject of 4 research reports in the past 90 days.Read more about Lantheus' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth11.35% Earnings GrowthEarnings for Lantheus are expected to grow by 11.35% in the coming year, from $5.99 to $6.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 18.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 18.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.15.Price to Book Value per Share RatioLantheus has a P/B Ratio of 9.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.94% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Lantheus has recently decreased by 1.44%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.67 Percentage of Shares Shorted5.94% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Lantheus has recently decreased by 1.44%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment1.42 News SentimentLantheus has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Lantheus this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat Follows7 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,689,156.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Stock News HeadlinesIs Lantheus Holdings (LNTH)The Most Undervalued Quality Stock To Buy According To Analysts?October 12, 2024 | msn.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives $126.00 Consensus Target Price from BrokeragesOctober 9, 2024 | americanbankingnews.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.October 17, 2024 | Porter & Company (Ad)Lantheus Holdings (NASDAQ:LNTH) Is Very Good At Capital AllocationOctober 8, 2024 | finance.yahoo.comRobust Quarterly Result Lifted Lantheus (LNTH) in Q2September 25, 2024 | finance.yahoo.comQuestor: A 300pc share price rise reflects the value of this cancer spotterSeptember 25, 2024 | msn.comLantheus Holdings (NASDAQ:LNTH) shareholder returns have been fantastic, earning 306% in 3 yearsSeptember 18, 2024 | finance.yahoo.comBuy Rating Reaffirmed for Lantheus Holdings Amid Promising PNT2002 Trial ResultsSeptember 18, 2024 | markets.businessinsider.comSee More Headlines LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $62.00 on January 1st, 2024. Since then, LNTH stock has increased by 86.5% and is now trading at $115.65. View the best growth stocks for 2024 here. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Wednesday, July, 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by $0.07. The firm's quarterly revenue was up 22.5% compared to the same quarter last year. When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Top institutional investors of Lantheus include Reinhart Partners LLC. (1.79%), Swedbank AB (1.04%), Shaker Investments LLC OH (0.06%) and Creative Planning (0.04%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden, Minnie Baylor-Henry and Carol Walker. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings7/31/2024Today10/17/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees834Year FoundedN/APrice Target and Rating Average Stock Price Target$126.00 High Stock Price Target$175.00 Low Stock Price Target$100.00 Potential Upside/Downside+8.9%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$6.55 Trailing P/E Ratio18.96 Forward P/E Ratio19.31 P/E GrowthN/ANet Income$326.66 million Net Margins29.80% Pretax Margin38.53% Return on Equity48.36% Return on Assets24.28% Debt Debt-to-Equity Ratio0.55 Current Ratio4.68 Quick Ratio4.41 Sales & Book Value Annual Sales$1.44 billion Price / Sales5.57 Cash Flow$7.14 per share Price / Cash Flow16.20 Book Value$11.91 per share Price / Book9.71Miscellaneous Outstanding Shares69,313,000Free Float68,390,000Market Cap$8.02 billion OptionableOptionable Beta0.50 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:LNTH) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
